Terms: = Lymphoma AND CALR, ENSG00000179218, 811, P27797, SSA, RO, FLJ26680, cC1qR AND Treatment
166 results:
1. Concurrent remission of lymphoma and Sjögren's disease following anti-CD19 chimeric antigen receptor-T cell therapy for diffuse large B-cell lymphoma: a case report.
Sheng L; Zhang Y; Song Q; Jiang X; Cao W; Li L; Yi H; Weng X; Chen S; Wang Z; Wu W; Wang L; Zhao W; Yan Z
Front Immunol; 2023; 14():1298815. PubMed ID: 38173731
[TBL] [Abstract] [Full Text] [Related]
2. A rare case of cutaneous lupus erythematosus presenting with periorbital erythema and edema.
Hacınecipoğlu F; Çevirgen Cemil B; Kartal SP; Arslankoz S
Lupus; 2024 Feb; 33(2):183-186. PubMed ID: 38148123
[TBL] [Abstract] [Full Text] [Related]
3. EBF1, MYO6 and calr expression levels predict therapeutic response in diffuse large B-cell lymphomas.
Turdo A; Gaggianesi M; D'Accardo C; Porcelli G; Bella SD; Cricchio D; Pillitteri I; Porcasi R; Lo Iacono M; Verona F; Modica C; Roozafzay N; Florena AM; Stassi G; Mancuso S; Todaro M
Front Immunol; 2023; 14():1266265. PubMed ID: 38035116
[TBL] [Abstract] [Full Text] [Related]
4. Mycosis fungoides with spongiosis: a case report.
Kashabano JJ; Rugengamazi E; Matiku SB; Mruma RM; Lugina EL
J Med Case Rep; 2023 Nov; 17(1):458. PubMed ID: 37919795
[TBL] [Abstract] [Full Text] [Related]
5. [Salivary gland ultrasound or biopsy? : Comparison of methods based on case examples].
Peters J; Timme-Bronsert S; Voll RE; Finzel S
Z Rheumatol; 2023 Oct; 82(8):654-665. PubMed ID: 37782326
[TBL] [Abstract] [Full Text] [Related]
6. The feasibility of implementing Toronto childhood cancer stage guidelines and estimating the impact on outcome for childhood cancers in seven pediatric oncology units in sub-Saharan Africa. A study from the Franco-African Pediatric Oncology Group.
Mallon B; Kaboré R; Couitchere L; Akonde FB; Narison MLR; Budiongo A; Dackono TA; Pondy A; Diedhiou F; Patte C; Steliarova-Foucher E; Clavel J
Pediatr Blood Cancer; 2023 Dec; 70(12):e30664. PubMed ID: 37732944
[TBL] [Abstract] [Full Text] [Related]
7. Significant heterogeneity in management of calreticulin-mutated essential thrombocythemia and its progression to myelofibrosis: results of a national survey.
Murton A; Forsyth C; Ross DM; Grigg A
Leuk Lymphoma; 2023 Dec; 64(12):2018-2025. PubMed ID: 37574855
[TBL] [Abstract] [Full Text] [Related]
8. Enhancing information on stage at diagnosis for childhood cancer in Africa.
Liu B; Abraham N; Chitsike I; Sylvie CGL; Kambugu J; Stévy NMA; Pondy AHO; Renner L; Parkin DM
Pediatr Blood Cancer; 2023 Oct; 70(10):e30555. PubMed ID: 37432023
[TBL] [Abstract] [Full Text] [Related]
9. Orelabrutinib versus ibrutinib for patients with refractory/relapsed primary central nervous system lymphoma: An efficacy and safety analysis.
Qiao L; Liu Q; Huang C
Medicine (Baltimore); 2023 Jul; 102(27):e33880. PubMed ID: 37417642
[TBL] [Abstract] [Full Text] [Related]
10. Guideline Concordance of treatment and Outcomes Among Adult Non-Hodgkin lymphoma Patients in Sub-Saharan Africa: A Multinational, Population-Based Cohort.
Mezger NCS; Hämmerl L; Griesel M; Seraphin TP; Joko-Fru YW; Feuchtner J; Zietsman A; Péko JF; Tadesse F; Buziba NG; Wabinga H; Nyanchama M; Chokunonga E; Kéita M; N'da G; Lorenzoni CF; Akele-Akpo MT; Mezger JM; Binder M; Liu B; Bauer M; Henke O; Jemal A; Kantelhardt EJ
Oncologist; 2023 Nov; 28(11):e1017-e1030. PubMed ID: 37368350
[TBL] [Abstract] [Full Text] [Related]
11. Analysis of Cancer Research Projects in Sub-Saharan Africa: A Quantitative Perspective on Unmet Needs and Opportunities.
Davies L; Milner DA; Shulman LN; Kyokunda L; Bedada A; Vuylsteke P; Masalu N; Jackson P; Jennings N; Odunlami A; Mtshali P; Dugan U
JCO Glob Oncol; 2023 Jun; 9():e2200203. PubMed ID: 37290022
[TBL] [Abstract] [Full Text] [Related]
12. Survival differences between patients with de novo and relapsed/progressed advanced non-small cell lung cancer without epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements.
Oh BC; Cho AR; Nam JH; Yang SY; Kim MJ; Kwon SH; Lee EK
BMC Cancer; 2023 May; 23(1):482. PubMed ID: 37248452
[TBL] [Abstract] [Full Text] [Related]
13. Distinctive Attributes of Indian Patients With Classical BCR::ABL1 Negative Myeloproliferative Neoplasms: Unified Clinical and Laboratory Data.
Singh S; Singh J; Mehta A; Sharma R; Joshi K; Jain K; Paul D; Oberoi G; Jindal N; Dhillon B; Narang V
Clin Lymphoma Myeloma Leuk; 2023 May; 23(5):360-369.e1. PubMed ID: 36849307
[TBL] [Abstract] [Full Text] [Related]
14. [Lymphoplasmacytic lymphoma accompanied by severe myelofibrosis].
Takarada A; Momose H; Kurita N; Matsuoka R; Nakamura N; Sakamoto T; Kato T; Hattori K; Suehara Y; Yokoyama Y; Nishikii H; Maruyama Y; Obara N; Chiba S; Sakata-Yanagimoto M
Rinsho Ketsueki; 2023; 64(1):54-59. PubMed ID: 36775308
[TBL] [Abstract] [Full Text] [Related]
15. Dynamics of Age- versus Therapy-Related Clonal Hematopoiesis in Long-term Survivors of Pediatric Cancer.
Hagiwara K; Natarajan S; Wang Z; Zubair H; Mulder HL; Dong L; Plyler EM; Thimmaiah P; Ma X; Ness KK; Li Z; Mulrooney DA; Wilson CL; Yasui Y; Hudson MM; Easton J; Robison LL; Zhang J
Cancer Discov; 2023 Apr; 13(4):844-857. PubMed ID: 36751942
[TBL] [Abstract] [Full Text] [Related]
16. Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated Peripheral T-Cell lymphoma: results of the PTCL13 phase Ib/II study.
Chiappella A; Dodero A; Evangelista A; Re A; Orsucci L; Usai SV; Castellino C; Stefoni V; Pinto A; Zanni M; Ciancia R; Ghiggi C; Rossi FG; Arcari A; Ilariucci F; Zilioli VR; Flenghi L; Celli M; Volpetti S; Benedetti F; Ballerini F; Musuraca G; Bruna R; Patti C; Leonardi F; Arcaini L; Magagnoli M; Cavallo F; Bermema A; Tucci A; Boccomini C; Ciccone G; Carniti C; Pileri SA; Corradini P
Leukemia; 2023 Feb; 37(2):433-440. PubMed ID: 36653509
[TBL] [Abstract] [Full Text] [Related]
17. TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma.
Erazo T; Evans CM; Zakheim D; Chu KL; Refermat AY; Asgari Z; Yang X; Da Silva Ferreira M; Mehta S; Russo MV; Knezevic A; Zhang XP; Chen Z; Fennell M; Garippa R; Seshan V; de Stanchina E; Barbash O; Batlevi CL; Leslie CS; Melnick AM; Younes A; Kharas MG
Nat Commun; 2022 Sep; 13(1):5676. PubMed ID: 36167829
[TBL] [Abstract] [Full Text] [Related]
18. Access to and Affordability of World Health Organization Essential Medicines for Cancer in Sub-Saharan Africa: Examples from Kenya, Rwanda, and Uganda.
Kizub DA; Naik S; Abogan AA; Pain D; Sammut S; Shulman LN; Martei YM
Oncologist; 2022 Nov; 27(11):958-970. PubMed ID: 36094141
[TBL] [Abstract] [Full Text] [Related]
19. The role of infections in the causation of cancer in Kenya.
Tuei VC; Maiyoh GK; Ndombera FT
Cancer Causes Control; 2022 Dec; 33(12):1391-1400. PubMed ID: 36087193
[TBL] [Abstract] [Full Text] [Related]
20. Saikosaponin A Inhibits Growth of Human Bladder Carcinoma T24 and 5637 Cells Both in Vitro and in Vivo.
Zhou Q; Wu WW; Yu CL; Wang P; Wen XQ; Chen BL; Zhang Y; Zhuang M; Zhang MY; Zhang HY; Zhang JW
Biol Pharm Bull; 2022 Jul; 45(7):863-871. PubMed ID: 35491088
[TBL] [Abstract] [Full Text] [Related]
[Next]
